Arizona’s attorney general is suing Insys Therapeutics over its marketing of the fentanyl opioid spray, Subsys, and that news caused the company’s shares to tumble 18.5% in August, according to S&P Global Market Intelligence.
Tag Archives: Syndros
If you look around, chances are you won’t find many marijuana stocks struggling. But there’s always an outlier — and for the marijuana industry that’s drugmaker Insys Therapeutics.
Insys Therapeutics is one of several biotechs developing cannabinoid drugs. Unlike most of these other companies, though, Insys has already won regulatory approval for its first cannabinoid — Syndros.
Here’s why these three cannabis stocks are in better shape than most others in the market. Take a deeper look into GW Pharmaceuticals, Insys Therapeutics, and Aphria.
As of April 13, 2017, more than 10.4 million shares of Insys Therapeutics (NASDAQ: INSY) were sold short. That’s 44% of the marijuana stock’s float. Investors have clearly bet big against Insys, anticipating that the stock will sink.
Marijuana stocks are extremely risky. But, if things go right for these pot stocks over the next two to three years, they could be a steal for investors.
Insys Therapeutics dropped after it received disappointing news from the DEA regarding its marijuana drug Syndros.
Insys Therapeutics’ stock rose on good news — but not tremendously so.
Most myths have at least a little bit of truth interspersed with a lot that is false. That’s the case with these three myths about marijuana stocks that some might mistakenly believe.
Let’s take a look back on this past year and see what the future holds for marijuana stocks.
PHOENIX, Aug. 3, 2016 /Weed Wire/ — Insys Therapeutics, Inc. (NASDAQ:INSY) (“Insys” or “the Company”) today announced financial results for the three-month period ended June 30, 2016.
As the debate around medical marijuana rages on, the Food and Drug Administration has approved a synthetic version of the substance. The recently approved Syndros, manufactured by Insys Therapeutics, is a liquid form of dronabinol, a synthesized version of THC.
PHOENIX, May 24, 2016 /Weed Wire/ — Insys Therapeutics, Inc. (NASDAQ: INSY) (“Insys” or “the Company”) today announced that it has successfully completed its Phase 1/Phase 2 safety and pharmacokinetic (PK) study in pediatric subjects with treatment-resistant epilepsy.